← FDA DRUG APPROVALS

FDA NDA · NDA209847

DARUNAVIR AND RITONAVIR

Sponsor: MYLAN PHARMS INC

APPLICATION
NDA209847
TYPE
NDA
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

DARUNAVIR AND RITONAVIRPrescription
DARUNAVIR AND RITONAVIR 400MG/50MG · TABLET · ORAL

Approval history

2023-12-22Type 4 - New Combination · Original · priority — Letter ↗TA
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →